BACKGROUND: Participation in first human applications of retinal neuroprosthesis may create psychological stress for blind retinitis pigmentosa patients. The aim of this study was to assess the emotional wellbeing of patients undergoing implantation of a subretinal implant. METHODS: Nine blind patients participating in a pilot trial with subretinal implants were enlisted. The Brief Symptom Inventory (BSI), a short self-report scale of nine primary symptoms, was used to assess reaction to the psychological distress related to study participation. The number and the intensity of symptoms were analysed, and global scores for overall psychological distress (tGSI), severity of reported symptoms (tPDSI), and level number of self-reported symptoms (tPST) were calculated. The questionnaire was administered before implantation, 2-3 times during the trial and before explantation. RESULTS: There were no significant alterations during the trial for the average scores of the nine primary symptoms. One patient, however, showed values higher than the norm, for six subscores before implantation and for eight subscores before explantation. A significant improvement was found in both the overall psychological distress level (tGSI) and the severity of reported symptoms (tPDSI) at the final visit, compared to those at the study start. The number of self-reported symptoms (tPST) was not significantly altered. CONCLUSION: In the first ongoing pilot trial with an active, cable-bound subretinal implant, we found that trial participation and the implant procedure and subsequent testing did not have any adverse effects on the participants' emotional wellbeing. Their distress generally improved during study participation, rather than showing signs of decreased wellbeing.
RCT Entities:
BACKGROUND: Participation in first human applications of retinal neuroprosthesis may create psychological stress for blind retinitis pigmentosapatients. The aim of this study was to assess the emotional wellbeing of patients undergoing implantation of a subretinal implant. METHODS: Nine blindpatients participating in a pilot trial with subretinal implants were enlisted. The Brief Symptom Inventory (BSI), a short self-report scale of nine primary symptoms, was used to assess reaction to the psychological distress related to study participation. The number and the intensity of symptoms were analysed, and global scores for overall psychological distress (tGSI), severity of reported symptoms (tPDSI), and level number of self-reported symptoms (tPST) were calculated. The questionnaire was administered before implantation, 2-3 times during the trial and before explantation. RESULTS: There were no significant alterations during the trial for the average scores of the nine primary symptoms. One patient, however, showed values higher than the norm, for six subscores before implantation and for eight subscores before explantation. A significant improvement was found in both the overall psychological distress level (tGSI) and the severity of reported symptoms (tPDSI) at the final visit, compared to those at the study start. The number of self-reported symptoms (tPST) was not significantly altered. CONCLUSION: In the first ongoing pilot trial with an active, cable-bound subretinal implant, we found that trial participation and the implant procedure and subsequent testing did not have any adverse effects on the participants' emotional wellbeing. Their distress generally improved during study participation, rather than showing signs of decreased wellbeing.
Authors: D Besch; H Sachs; P Szurman; D Gülicher; R Wilke; S Reinert; E Zrenner; K U Bartz-Schmidt; F Gekeler Journal: Br J Ophthalmol Date: 2008-07-28 Impact factor: 4.638
Authors: Eberhart Zrenner; Karl Ulrich Bartz-Schmidt; Heval Benav; Dorothea Besch; Anna Bruckmann; Veit-Peter Gabel; Florian Gekeler; Udo Greppmaier; Alex Harscher; Steffen Kibbel; Johannes Koch; Akos Kusnyerik; Tobias Peters; Katarina Stingl; Helmut Sachs; Alfred Stett; Peter Szurman; Barbara Wilhelm; Robert Wilke Journal: Proc Biol Sci Date: 2010-11-03 Impact factor: 5.349
Authors: Mohammad Hossein Maghami; Amir Masoud Sodagar; Alireza Lashay; Hamid Riazi-Esfahani; Mohammad Riazi-Esfahani Journal: J Ophthalmic Vis Res Date: 2014 Oct-Dec